References
- Daly MB, Pilarski R, Berry M, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):77–102.
- Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic counseling, and genetic testing for BRCA -related cancer. JAMA. 2019;322(7):652.
- Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin oncol. 2004;22(6):1055–1062.
- Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
- Norum J, Grindedal EM, Heramb C, et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO open. 2018;3(3):e000328.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032–18037. https://pubmed.ncbi.nlm.nih.gov/22006311/
- Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018;110(7):714–725.
- Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269–275.
- Jervis S, Song H, Lee A, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet. 2015;52(7):465–475.
- Wurtzel E, ‘Prozac Nation’ Author, Is Dead at 52 - The New York Times [cited 2020 Jan 12]. https://www.nytimes.com/2020/01/07/books/elizabeth-wurtzel-dead.html.
- Opinion | the breast cancer gene and me - The New York Times [cited 2019 Oct 11]. https://www.nytimes.com/2015/09/27/opinion/sunday/elizabeth-wurtzel-the-breast-cancer-gene-and-me.html?smid=nytcore-ios-share.
- Program SR. SEER
- Arias E, Xu J, Kochanek KD National Vital Statistics Reports Volume 68, Number 4 May 7, 2019 United StatesLife Tables, 2016. Vol 68; [cited 2019 Oct 11]. https://www.cdc.gov/nchs/products/index.htm.
- Toland AE, Forman A, Couch FJ, et al. Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. NPJ Genom Med. 2018;3(1). DOI:10.1038/s41525-018-0046-7
- Evans DGR, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2318–2324.
- Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–590.
- Jacobi CE, Jonker MA, Nagelkerke NJ D, et al. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. J Med Genet. 2003;40. DOI:10.1136/jmg.40.7.e83.
- de Felice F, Marchetti C, Musella A, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol. 2015;22(9):2876–2880.
- Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.
- Manchanda R, Burnell M, Loggenberg K, et al. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J Med Genet. 2016;53(7):472–480.
- Color genomics [cited 2019 Oct 11]. http://www.color.com/.
- Schwartz MD, Valdimarsdottir HB, Peshkin BN, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin oncol. 2014;32(7):618–626.
- Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18(4):51–64.
- Fu AZ, Chen L, Sullivan SD, et al. Absenteeism and short-term disability associated with breast cancer. Breast Cancer Res Treat. 2011;130(1):235–242.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. Available from: https://www.nice.org.uk/guidance/ta235/resources/osteosarcoma-mifamurtide-discounting-of-health-benefits-in-special-circumstances2
- Briggs A Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):1–2. https://pubmed.ncbi.nlm.nih.gov/15841888/.
- Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med. 2017;376(3):203–205.
- Armstrong N, Ryder S, Forbes C, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019 Jul 11;11; 543–561. DOI:10.2147/CLEP.S206949.